What Tango Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 8 | 25 |
| Total trades | 11 | 46 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 81,000 | 799,382 |
| Disposed | 89,200 | 381,544 |
| Net activity | −8,200 | +417,838 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Crystal Adam | President, R&D | Oct 01 | Open-market sale · S | −600 | $25.32 | −$15.2K | 115,743 |
| Crystal Adam | President, R&D | Oct 01 | Open-market sale · S | −26,400 | $24.45 | −$646K | 116,343 |
| Crystal Adam | President, R&D | Oct 01 | Exercise / conversion · M | +27,000 | $5.20 | +$140K | 142,743 |
| Newcomb Jessica | Principal Accounting Officer | Sep 22 | Open-market sale · S | −2,400 | $25.17 | −$60.4K | 59,121 |
| Newcomb Jessica | Principal Accounting Officer | Sep 22 | Open-market sale · S | −5,100 | $23.97 | −$122K | 61,521 |
| Newcomb Jessica | Principal Accounting Officer | Sep 22 | Open-market sale · S | −700 | $22.80 | −$16K | 66,621 |
| Crystal Adam | President, R&D | Sep 01 | Open-market sale · S | −27,000 | $22.37 | −$604K | 115,743 |
| Crystal Adam | President, R&D | Sep 01 | Exercise / conversion · M | +27,000 | $5.20 | +$140K | 142,743 |
| Crystal Adam | President, R&D | Aug 03 | Open-market sale · S | −21,733 | $27.35 | −$594K | 115,743 |
| Crystal Adam | President, R&D | Aug 03 | Open-market sale · S | −5,267 | $26.79 | −$141K | 137,476 |
| Crystal Adam | President, R&D | Aug 03 | Exercise / conversion · M | +27,000 | $5.20 | +$140K | 142,743 |
| Crystal Adam | President, R&D | Jul 01 | Open-market sale · S | −7,371 | $30.25 | −$223K | 115,743 |
| Crystal Adam | President, R&D | Jul 01 | Open-market sale · S | −19,629 | $29.34 | −$576K | 123,114 |
| Crystal Adam | President, R&D | Jul 01 | Exercise / conversion · M | +27,000 | $5.20 | +$140K | 142,743 |
| Azelby Robert | Director | Jun 19 | Grant / award · A | +5,740 | — | — | 5,740 |
| Lee Sung | Director | Jun 05 | Grant / award · A | +570 | — | — | 22,870 |
| Calhoun Lesley Ann | Director | Jun 05 | Grant / award · A | +4,000 | — | — | 16,500 |
| Rothenberg Mace | Director | Jun 05 | Grant / award · A | +4,000 | — | — | 41,500 |
| Ketchum John B | Director | Jun 05 | Grant / award · A | +4,000 | — | — | 24,937 |
| Crystal Adam | President, R&D | Jun 01 | Open-market sale · S | −20,860 | $23.06 | −$481K | 115,743 |
Loading...
